Reverse merger run extends as Marea, North Immunology line up deals with $405M in backing
Reverse merger run extends as Marea, North Immunology line up deals with $405M in backing
Marea Therapeutics
Private
Clinical-stage cardioendocrine company developing MAR001, an antibody targeting remnant cholesterol, and MAR002 for acromegaly.
Company Info
Sector:Biotechnology / Cardiometabolic
Headquarters:South San Francisco, California, USA
Founded:2024
Website:www.mareatx.com/
Funding Round:Series A
Funding & Investor Relations
Notable Investors
- Third Rock Ventures